You are here:

cobicistat (Tybost)

Advice

in the absence of a submission from the holder of the marketing authorisation

cobicistat (Tybost®) is not recommended for use within NHS Scotland.

Indication under review: Pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: cobicistat (Tybost)
SMC Drug ID: 933/13
Manufacturer: Gilead Sciences Ltd
Indication: Pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 May 2014

Back